Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge represents the owners of Axel Arigato AB in connection with investment from Eurazeo
Mandate

Vinge represents the owners of Axel Arigato AB in connection with investment from Eurazeo

November 09, 2020 M&A

Vinge represents the owners of Axel Arigato AB in connection with Eurazeo Brands the investment from of EUR 56 million into the company.

Through the investment, Eurazeo Brands becomes the company’s majority owner, alongside Axel Arigato’s founders, Albin Johansson and Max Svärdh.

Axel Arigato AB was established in 2014 and is a fast-growing fashion company within the premium segment for sneakers and streetwear. Eurazeo Brands is a division within the publicly listed French investment company Eurazeo SE.

The Vinge team consisted primarily of Jesper Ottergren and Charlotte Akej.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026